Blarcamesine appeared to slow the decline of cognition and functional capacity for people with Alzheimer’s disease in a long-term trial.| Alzheimer's News Today
A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug Administration.| Alzheimer's News Today
Leqembi, Eisai and Biogen’s amyloid-targeted antibody therapy, has earned FDA approval for the treatment of Alzheimer’s disease.| Alzheimer's News Today
Leqembi has been approved in the European Union for the treatment of certain adults with early Alzheimer's disease and mild cognitive issues.| Alzheimer's News Today
A rare APOE gene mutation may protect against Alzheimer's by stopping the spread of toxic tau protein clumps in the brain, a study found.| Alzheimer's News Today
Lindsey Shapiro is a science writer for Alzheimer's News Today with a PhD in neuroscience. She covers the latest news and information on a variety of Alzheimer's topics.| Alzheimer's News Today
Under-the-skin injections worked better in trial than the approved Leqembi formulation in clearing harmful amyloid plaques in Alzheimer's.| Alzheimer's News Today
The immunotherapy Leqembi, formerly BAN2401, is now FDA-approved for slowing cognitive decline in patients with Alzheimer's disease.| Alzheimer's News Today
Kisunla (donanemab-azbt) is an antibody-based therapy approved in the U.S. for adults with early symptomatic Alzheimer’s disease.| Alzheimer's News Today
There is great value in the relationship between grandparents and grandchildren, columnist Ray Burow says, even if Alzheimer's is involved.| Alzheimer's News Today
Eli Lilly's donanemab, now Kisunla, was approved by the U.S. Food and Drug Administration for patients with early symptomatic Alzheimer’s.| Alzheimer's News Today
Category archive page for News.| Alzheimer's News Today
Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers.| Alzheimer's News Today